BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Leong WI, Ames RY, Haverkamp JM, et al. (2019) Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. Oncotarget. 10: 7220-7237
Kell SA, Kachura MA, Renn A, et al. (2019) Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells. International Immunopharmacology. 66: 296-308
Degagné É, Romo J, Gallotta M, et al. (2019) Abstract 2259: Tumor abscopal responses induced by the TLR9 agonist, SD-101, are strongly potentiated by a HDAC class I inhibitor, domatinostat Cancer Research. 79: 2259-2259
Ribas A, Medina T, Kummar S, et al. (2018) SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase 1b, Multicenter Study. Cancer Discovery
Frank MJ, Reagan PM, Bartlett NL, et al. (2018) In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery
Gallotta M, Assi H, Degagné É, et al. (2018) Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay. Cancer Research
Jackson S, Candia AF, Delaney S, et al. (2017) First-in-human study with the inhaled TLR9 oligonucleotide agonist AZD1419 results in interferon responses in the lung, and is safe and well-tolerated. Clinical Pharmacology and Therapeutics
Sato-Kaneko F, Yao S, Ahmadi A, et al. (2017) Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. Jci Insight. 2
Candia A, Guiducci C, Coffman RL, et al. (2017) Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01) Cancer Research. 77
Naik E, Ying C, Milley R, et al. (2017) Abstract 5596: Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration Cancer Research. 77: 5596-5596
See more...